The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Therapeutic antibody fragments with prolonged in vivo half-lives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Assembly of a Functional Immunoglobulin F v Fragment in Escherichia coli
Skerra, A., & Plückthun, A. (1988) · Science · doi:10.1126/science.3285470 · Cited by 978
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., & Yarranton, G. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-169 · Cited by 462
Self-citationHigh Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment
Carter, P., Kelley, R. F., Rodrigues, M. L., Snedecor, B., Covarrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts, C. E., Carver, M. E., et al. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-163 · Cited by 330
RANKIN, E. C. C., CHOY, E. H. S., KASSIMOS, D., KINGSLEY, G. H., SOPWTTH, A. M., ISENBERG, D. A., & PANAYI, G. S. (1995) · Rheumatology · doi:10.1093/rheumatology/34.4.334 · Cited by 231
Stabilization of Substances in Circulation
Monfardini, C., & Veronese, F. M. (1998) · Bioconjugate Chemistry · doi:10.1021/bc970184f · Cited by 213
Vaughan, T. J., Osbourn, J. K., & Tempest, P. R. (1998) · Nature Biotechnology · doi:10.1038/nbt0698-535 · Cited by 158
Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
King, D., Turner, A. V., Farnsworth, A., Adair, J. R., Owens, R. J., Pedley, R. B., Baldock, D., Proudfoot, K. A., Lawson, A. D. G., & Beeley, N. (1994) · PubMed · Cited by 125
Self-citationKitamura, K., Takahashi, T., Yamaguchi, T., Noguchi, A., Noguchi, A., Takashina, K., Tsurumi, H., Inagake, M., Toyokuni, T., & Hakomori, S. (1991) · PubMed · Cited by 76
Pedley, R. B., Boden, J. A., Boden, R. W., Begent, R., Turner, A. V., Haines, A., & King, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.459 · Cited by 58
Self-citation
Cited by
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
PEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Saito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence
Chinen, A. B., Guan, C. M., Ferrer, J. R., Barnaby, S. N., Merkel, T. J., & Mirkin, C. A. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00321 · Cited by 1,032
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
Caliceti, P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00108-x · Cited by 947
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Seebach, D., & Gardiner, J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700263g · Cited by 709
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Polymer–drug conjugation, recent achievements and general strategies
Pasut, G., & Veronese, F. M. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.008 · Cited by 616
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Self-citationThe Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Fishburn, C. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21278 · Cited by 474
Introduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
Kohler, N., Fryxell, G. E., & Zhang, M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja049195r · Cited by 466
Polymer conjugates: nanosized medicines for treating cancer
Vicent, M. J., & Duncan, R. (2006) · Trends in Biotechnology · doi:10.1016/j.tibtech.2005.11.006 · Cited by 443
van Oss, C. J. (2003) · Journal of Molecular Recognition · doi:10.1002/jmr.618 · Cited by 388
PEG-modified biopharmaceuticals
Bailon, P., & Won, C.-Y. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802650568 · Cited by 366
Antibodies and Genetically Engineered Related Molecules: Production and Purification
Roque, A. C. A., Lowe, C. R., & Taipa, M. A. (2004) · Biotechnology Progress · doi:10.1021/bp030070k · Cited by 360
Mono-N-terminal poly(ethylene glycol)–protein conjugates
Kinstler, O., Molineux, G., Treuheit, M., Ladd, D., & Gegg, C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00023-6 · Cited by 306
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 289
Nanobody-Based Cancer Therapy of Solid Tumors
Kijanka, M., Dorresteijn, B., Oliveira, S., & van Bergen en Henegouwen, P. M. (2015) · Nanomedicine · doi:10.2217/nnm.14.178 · Cited by 265
Biological–synthetic hybrid block copolymers: Combining the best from two worlds
Klok, H. (2005) · Journal of Polymer Science Part A: Polymer Chemistry · doi:10.1002/pola.20527 · Cited by 265
Maleimide–thiol adducts stabilized through stretching
Huang, W., Wu, X., Gao, X., Yu, Y., Lei, H., Zhu, Z., Shi, Y., Chen, Y., Qin, M., Wang, W., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0209-2 · Cited by 258
Nanobodies to Study G Protein–Coupled Receptor Structure and Function
Manglik, A., Kobilka, B. K., & Steyaert, J. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104710 · Cited by 257
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
Maruani, A., Smith, M. E. B., Miranda, E., Chester, K. A., Chudasama, V., & Caddick, S. (2015) · Nature Communications · doi:10.1038/ncomms7645 · Cited by 256
Kang, J. S., DeLuca, P. P., & Lee, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902907847 · Cited by 252
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
Smith, B., Kiessling, A., Lledo-Garcia, R., Dixon, K. L., Christodoulou, L., Catley, M. C., Atherfold, P., D’Hooghe, L. E., Finney, H., Greenslade, K., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1505464 · Cited by 117
Self-citationHumphreys, D. P., Carrington, B., Bowering, L. C., Ganesh, R., Sehdev, M., Smith, B. J., King, L. M., Reeks, D. G., Lawson, A., & Popplewell, A. G. (2002) · Protein Expression and Purification · doi:10.1016/s1046-5928(02)00543-0 · Cited by 54
Metadata
- Authors
- Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J.
- Venue
- Nature Biotechnology
- Published
- 1999-08
- Volume
- 17
- Issue
- 8
- Pages
- 780-783
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1578375703
- Cited by
- 350
- References
- 12
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.